La chaîne d'options affiche les données clés des options sur actions de Artelo Biosciences à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Artelo Biosciences..

Artelo Biosciences (NASDAQ:ARTL) Stock, Chaîne d'Options

ARTELO BIOSCIENCES INC

Artelo Biosciences

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Artelo Biosciences Inc

Artelo Biosciences Inc Warrants (18/06/2024)

Nayax Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) reported mixed results for the <a href="https://www.benzinga.com/quote/NYAX/earnings">first quarter on Tuesday</a>.
The company posted quarterly earnings of 19 cents per share which beat the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million.
&#8220;Nayax is off to an excellent start in 2025 as we continue to execute on driving profitable topline growth, improving our recurring revenue mix, increasing our market share, and expanding our geographic footprint. As a key milestone, we ended the quarter with more than 100,000 customers globally, which is a testament to both Nayax being a trusted partner and a leading payments company. I couldn&#8217;t be more pleased with where we are today as we continue to scale the business for the long term&#8221;, commented Yair Nechmad, Chief Executive Officer and Chairman of the Board.
Nayax affirmed its FY2025 sales guidance of $410.00 million to $425.00 million.
Nayax shares gained 3.3% to trade at $41.03 on Wednesday.
These analysts made changes to their price targets on Nayax following earnings announcement.
<ul class="wp-block-list">
<li>B. Riley Securities analyst Josh Nichols maintained Nayax with a Buy and raised the price target from $44 to $47.</li>
<li>Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintained the stock with a Market Perform and raised the price target from $38 to $40.</li>
</ul>
Considering buying NYAX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125941/image-166-1024x596.png" alt="" class="wp-image-915387" style="width:663px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125941/image-166-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125941/image-166-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125941/image-166-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125941/image-166.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45403847/coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday">Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

NYAX

Nayax Analysts Raise Their Forecasts After Q1 Results

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Buy to Neutral.

Downgrades

ITOS

HC Wainwright & Co. Downgrades ITeos Therapeutics to Neutral

Discover Financial servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) short percent of float has risen 23.27% since its last report. The company recently reported that it has 5.45 million shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Discover Financial servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747242046_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Discover Financial servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Discover Financial servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Discover Financial servs's peer group average for short interest as a percentage of float is 7.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Discover Financial servs?

JP Morgan analyst Tami Zakaria maintains Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) with a Overweight and raises the price target from $84 to $88.

TRMB

JP Morgan Maintains Overweight on Trimble, Raises Price Target to $88

Blackstone's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) short percent of float has risen 10.46% since its last report. The company recently reported that it has 12.38 million shares sold short, which is 1.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Blackstone Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747242041_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blackstone has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Blackstone's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Blackstone's peer group average for short interest as a percentage of float is 3.92%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Blackstone?

Micron Technology's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MU#NYSE">MU</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 28.85 million shares sold short, which is 2.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Micron Technology Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747242036_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Micron Technology has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Micron Technology's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Micron Technology's peer group average for short interest as a percentage of float is 5.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Micron Technology's Recent Short Interest

<h4 class="wp-block-heading">SpaceX's valuation has been skyrocketing recently (pun fully intended)</h4>
<h4 class="wp-block-heading">But non-accredited investors can't get involved…until now.</h4>
<h4 class="wp-block-heading">Here's how you can get your feet wet in the $1.8 trillion space economy: </h4>
Most companies in the space industry are private because of:
• Government contracts
• National security concerns
• High R&amp;D costs + long timelines
But thankfully, there's a backdoor entrance to this sector.
I'm talking about a little-known government program.
It's called the Regulation A+ securities exemption.
It allows private companies to temporarily raise capital from the general public without undergoing an IPO.
And right now, a private company called&nbsp;Starfighters Space&nbsp;is doing exactly this.
Let me break down the details of the company and how to get involved &#x1f447;
Starfighters Space is an aerospace and defense company specializing in hypersonic testing and small satellite launch services.
They operate the world's only commercial fleet of flight-ready Lockheed F-104 aircraft.
How are they involved in the space industry?
Starfighters uses its supersonic F-104s to simulate and support space-related missions.
Such as:
• Testing spaceflight hardware
• Simulating suborbital spaceflights
• Conducting microgravity experiments
• Launching small payloads into the upper atmosphere
And so much more.
In a pinch,&nbsp;Starfighters&nbsp;helps companies put their satellites into space.
A commercial space application that's been picking up momentum recently.
This chart speaks for itself.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfbfs-5balTO6d1Scwa9NkG6BY3_bHEXjoFBLE3dYifEmh1iMjn7i23IdXpBE7d-sFwJLfpxsRfc3Q4bxpY5dKuWq_fiM7N6ZRpvsYMc4nHQtcgYeZUXaDt9patsrGDTFjbruagBw?key=An3c9u52TWn-cgVLN6x4zA" alt="" /></figure>
Why the sudden surge?
Thanks to Elon's SpaceX and Starlink.
Elon has created an explosion of investment interest in the space economy.
Motivating other companies and VCs to get involved.
The opportunity to invest in&nbsp;Starfighters Space&nbsp;won't last much longer.
They've already raised $21.7M of their $35M goal so far.
Once they reach their goal, this rare investment window will close.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd236XHhTU4v_qxvyY3wrNCa2qbXoJ0SnMuGtsZAZh6nAihJTJ0pwBqPbdZS1yfSRI7v94K_WYY9YXl4VP4KjE_kX1ek_7dtEOUfAulJhBA_ssjjPlinIOFr7DmXMr-OtLaJgifiw?key=An3c9u52TWn-cgVLN6x4zA" alt="" /></figure>
There's so much more to be bullish about.
But I could never express it all in a simple X thread.
If you'd like to learn more before potentially investing, visit the link below &#x1f447;
<a href="https://invest.equifund.com/offering/starfighters/details">https://invest.equifund.com/offering/starfighters/details</a>
Working with Starfighters to share this campaign with my audience is a pleasure.
Please remember that investing always involves risk, and that risk is elevated with smaller companies.
Always conduct thorough due diligence and gain full confidence before investing your hard-earned money.
&#x2A;&#x2A;
Hey there!
Welcome to the WOLF Financial Newsletter.
Join over 13,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
<a target="_blank" rel="noreferrer noopener" href="https://marketmadness-newsletter.beehiiv.com/subscribe">Subscribe</a>
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=skyrocketing-opportunities-invest-in-the-1-8-trillion-space-economy" target="_blank" rel="noreferrer noopener">Here</a>.

Equities

Long Ideas

SPACE

IPOs

Opinion

An Opportunity To Invest In The $1.8 Trillion Space Economy

In the current session, AstraZeneca Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) is trading at $66.27, after a 2.14% drop. Over the past month, the stock decreased by 1.16%, and in the past year, by 13.98%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1747242024_0.png" alt="Past Year Chart" />

<h3>A Look at AstraZeneca P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747242024_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for AstraZeneca

JP Morgan analyst Matthew Boss maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Neutral and lowers the price target from $10 to $9.

JP Morgan Maintains Neutral on American Eagle Outfitters, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) with a Buy rating and announces Price Target of $10.

Initiation

SABS

HC Wainwright & Co. Assumes SAB Biotherapeutics at Buy, Announces Price Target of $10

JP Morgan analyst Rahul Krotthapalli downgrades Krispy Kreme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) from Overweight to Neutral.

DNUT

JP Morgan Downgrades Krispy Kreme to Neutral

Technology giant and video game company Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) is among the companies that could be hit hard by tariffs on countries such as China and Japan.
The company has several ideas on how to offset tariffs from President Donald Trump.
What Happened: Sony reported fourth-quarter financials Wednesday with quarterly sales of $17.24 billion, down 24% year-over-year and coming in shy of a Street consensus estimate of $20.4 billion.
The company's Game &amp; Network Services segment saw sales down 4.2% year-over-year for the quarter. Sony said it sold 2.8 million PlayStation 5s in the quarter, down from 4.5 million in last year's fourth quarter and down from 9.5 million sold in the third quarter, which included the Christmas shopping season.
Along with its financial results, Sony shared guidance for the next year, which included comments that the company could face a $680 million impact from tariffs.
Sony is one of several video game companies that has considered raising the price of consoles to help offset tariffs. The company said Wednesday it will also consider moving manufacturing to the U.S. to avoid costly tariffs.
Sony Chief Financial Officer Lin Tao said the company is considering "passing on" tariffs to consumers to protect profits, as reported by The Verge. While Tao didn't name the PlayStation 5 specifically, this would confirm previous reports that the console could get more expensive for gamers in the U.S.
Along with potential price increases, Sony CEO Hiroki Totoki highlighted the potential to move PlayStation 5 production to the United States. Totoki said the console "can be produced locally," and said this could be "an efficient strategy" to offset tariffs.
"Has to be considered going forward," Totoki added.
Why It's Important: The PlayStation 5 is one of the top-selling video game consoles of all time and has sold significantly more units than the Xbox Series X/S from Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) during the current console cycle.
In the past 12 months, Sony has shipped 18.5 million PlayStation 5 consoles, bringing the lifetime total to 77.7 million, according to the report.
Sony manufactures the majority of PlayStation 5 hardware in China, which makes the tariffs on the country costly to the company's gaming division.
While the tariff amount declined from over 100% to 30% in a 90-day pause, Sony has to carefully consider whether it eats this cost, passes it onto the consumer or considers making future changes like its manufacturing processes.
Sony may want to have control of the situation and any potential tariff struggles down the road with the PlayStation 6 consol, rumored to be released in 2027 or 2028 and to help kick off the next console cycle.
SONY Price Action: Sony stock is up 1.22% to $24.84 on Wednesday versus a 52-week trading range of $15.67 to $26.08. Sony stock is up 18% year-to-date in 2025 and up over 50% in the last year.

Gaming

MSFT

Sony Group Corporation American Depositary Shares

SONY

Sony Could See $680 Million Tariff Impact, Considers Moving PlayStation 5 Production To US

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>B of A Securities analyst Fiona Liang initiated coverage on EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) with a Buy rating and announced a price target of $26. EHang shares closed at $19.24 on Tuesday. <a href="https://www.benzinga.com/quote/EH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Timothy Horan initiated coverage on Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) with an Outperform rating and announced a price target of $200. Digital Realty Trust shares closed at $165.80 on Tuesday. <a href="https://www.benzinga.com/quote/DLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Logan Reich initiated coverage on Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with an Outperform rating and announced a price target of $83. Dutch Bros shares closed at $70.23 on Tuesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group initiated coverage on Centrus Energy Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) with an Outperform rating and announced a price target of $145. Centrus Energy shares closed at $92.57 on Tuesday. <a href="https://www.benzinga.com/quote/LLEU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Bill Ryan initiated coverage on Enova International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Buy rating and announced a price target of $124. Enova International shares closed at $99.22 on Tuesday. <a href="https://www.benzinga.com/quote/ENVA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DLR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125146/image-165-1024x566.png" alt="" class="wp-image-915374" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125146/image-165-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125146/image-165-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125146/image-165-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14125146/image-165.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45403847/coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday">Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

BROS

ENVA

This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

WIIM

ETON

ETON stock has given up its prior gain. Eton Pharmaceuticals shares were trading higher after the company reported better-than-expected Q1 financial results.

Jefferies analyst Stephanie Moore maintains Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Hold and lowers the price target from $7 to $6.

Jefferies Maintains Hold on Hertz Global Holdings, Lowers Price Target to $6

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

Reiteration

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

<a href="https://www.bloomberg.com/news/articles/2025-05-14/us-is-not-negotiating-for-weaker-dollar-as-part-of-tariff-talks">https://www.bloomberg.com/news/articles/2025-05-14/us-is-not-negotiating-for-weaker-dollar-as-part-of-tariff-talks</a>
&nbsp;

Macro Economic Events

Global

Economics

PowerShares DB US Dollar Index Bullish Fund

'U.S. Not Seeking To Weaken Dollar As Part Of Trade Deals' - Bloomberg

Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong has called on Department of Government Efficiency contractors to apply to Coinbase to &#8220;help create a more efficient financial system for the world.&#8221;
What Happened: In a <a href="https://x.com/brian_armstrong/status/1922368587626643618">post</a> on X on May 13, Armstrong wrote &#8220;If you&#8217;re looking for your next mission to serve your country, consider taking the DOGE Staff interview, help us build a more efficient financial system for the world at Coinbase.&#8221;
He reposted a video featuring a Harvard dropout who joined the DOGE team, saying he found greater impact and purpose working on financial reform than in academia. 
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323509/coinbase-analysts-look-ahead-to-q2-after-disappointing-q1-higher-crypto-prices-increased-volumes">Coinbase Analysts Look Ahead To Q2 After Disappointing Q1: &#8216;Higher Crypto Prices… Increased Volumes&#8217;</a>
Why It Matters: Armstrong has long <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42035165/coinbase-ceo-brian-armstrong-says-doge-department-is-a-once-in-a-lifetime-opprtunity-advocates-abolishing-individual-income-tax">championed</a> DOGE as a vehicle for financial reform, previously describing it as a "once-in-a-lifetime opportunity" to expand economic freedom in the U.S. 
In November 2024, he even proposed replacing individual income tax with corporate taxation, highlighting DOGE's role in broader policy innovation.
More recently, in May 2025, Armstrong <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45309227/coinbase-ceo-brian-armstrong-believes-traditional-banks-launching-own-stablecoins-not-necessarily-the-best-path-pitches-usdc-as-option">noted</a> that stablecoins like USDC have strong network effects and urged banks to partner with existing players rather than creating their own.
In February 2025, Armstrong <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">likened</a> Bitcoin adoption to the early days of mobile phones and the internet, predicting billions of global users by 2030.
As Coinbase gains momentum, including its inclusion in the S&amp;P 500 Index, Armstrong's DOGE initiative may signal a deeper push toward financial system disruption from within the industry's top leadership.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45368175/cathie-wood-says-index-sensitive-managers-will-be-compelled-to-consider-coinbase-as-crypto-exchange-platform-joins-sp-500-index">Cathie Wood Says &#8216;Index-Sensitive Managers Will Be Compelled to Consider&#8217; Coinbase As Crypto Exchange Platform Joins S&amp;P 500 Index</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Coinbase CEO Brian Armstrong Invites DOGE Staff To 'Create A More Efficient Financial System'

Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) has outperformed the market over the past 20 years by 4.63% on an annualized basis producing an average annual return of 12.91%. Currently, Applied Industrial Techs has a market capitalization of $8.91 billion. 
Buying $100 In AIT: If an investor had bought $100 of AIT stock 20 years ago, it would be worth $1,157.94 today based on a price of $232.10 for AIT at the time of writing.
<h3>Applied Industrial Techs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747241213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) with a Buy and maintains $4 price target.

MOGO

HC Wainwright & Co. Reiterates Buy on Mogo, Maintains $4 Price Target

Health Care

Press Releases

General

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

ARTL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

CNS Pharma

Enveric Biosciences

Evoke Pharma

Eyenovia

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Comments

Artelo Biosciences

Artelo Biosciences (ARTL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL